Overview

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

Status:
Completed

Trial end date:
2020-01-01

Target enrollment:

Participant gender:

Summary

This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of mirvetuximab soravtansine to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced EOC, primary peritoneal cancer and/or fallopian tube cancer.

Phase:

Phase 3

Details

Lead Sponsor:

ImmunoGen, Inc.

Collaborator:

Gynecologic Oncology Group

Treatments:

Antibodies
Doxorubicin
Liposomal doxorubicin
Maytansine
Paclitaxel
Topotecan